Colorectal Cancer

New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer

2023-11-20

  • Study

    Phase 3, multicenter, open-label, randomized, active-controlled trial (CODEBREAK 300)
    KRAS G12 C mutant metatatic colorectal cancer, were disease progression or recurrence after receiving at least one previous line of therapy for metastatic diseas
    Sotorasib 960 mg + Panitimumab (n=53) vs. Sotorasib 240 mg + Panitimumab (n=53) vs. SOC (TAS-102; Regorafenib) (n=54


  • Efficacy

    mPFS: 5.6 vs. 3.9 vs. 2.2 mos, HR:0.49, p=0.006
    ORR: 34% vs. 11.3% vs. 1.9%

  • Safety

    Grade3: Dermatitis acneiform (11.8% vs.3% vs. 0), hypomagnesemia (5.75 vs. 7.5 % vs. 0), diarrhea (3.8% vs. 5.7% vs. 0)


    • N Engl J Med October 22, 2023

    Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

    http://doi.org/10.1056/NEJMoa2308795

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023